Responses
Original research
Interstitial lung disease in patients treated with poly (ADP-ribose) polymerase inhibitors (PARPi): analysis of results from clinical trials and the FDA Adverse Events Reporting System database
Compose a Response to This Article
Other responses
No responses have been published for this article.